



Claims

511) 59/ 5/

- 1. Pharmaceutical preparation containing as an active agent a pharmacologically acceptable salt of dichloromethylene bisphosphonic acid, characterized in that it is an oral solid dosage form comprising silicified microcrystalline cellulose.
- 2. Preparation according to claim 1, characterized in that it comprises 5-25 % by weight of silicified microerystalline cellulose.

300

- 3/Preparation according to claim 1, characterized in that it comprises a) from about 60 to 80 % by weight of anhydrous disodium clodronate;
- b) from about 8 to 20 % by weight of silicified microcrystalline cellulose; and
- c) from about 0.5 to 10 % by weight of lubricants and/or disintegrants.

15**a**

4. Preparation according to any one of the preceding claims wherein silicon dioxide is present in the silicified microcrystalline cellulose in an amount of from about 0.1 to 20 % by weight, based on the weight of the microcrystalline cellulose.

20 a


5. Preparation according to any one of the preceding claims, characterized in USL that it is a tablet or capsule.

Q 4

30

- 6. Preparation according to any one of the preceding claims, characterized in that the salt of dichloromethylene bisphosphonic acid is the disodium salt.
- 7. Process for the manufacture of a pharmaceutical preparation according to claim 1 characterized in that a wet granulation technique is used.
- 8. Process for the manufacture of a pharmaceutical preparation according to claim 1, characterized in that a dry granulation technique is used.





1, characterized in that a direct compression technique is used.

10. Use of silicified microcrystalline cellulose for the manufacture of a pharmaceutical preparation containing as an active agent a pharmacologically acceptable salt of dichloromethylene bisphosphopic acid.

WB17

5

O (